Hiển thị các bài đăng có nhãn against. Hiển thị tất cả bài đăng
Hiển thị các bài đăng có nhãn against. Hiển thị tất cả bài đăng

Thứ Sáu, 17 tháng 2, 2012

Antibiotics no help against most sinus infections

NEW YORK (Reuters Health) - Antibiotics don't help fight most sinus infections, although doctors routinely prescribe them for that purpose, researchers said Tuesday.

The medications are known to fuel the evolution of drug-resistant bacteria and experts have grown increasingly worried about overuse.

That's a particular concern with sinus infections, because doctors can't tell if the disease is caused by bacteria or by a virus, in which case antibiotics would be worthless.

The new study, published in the Journal of the American Medical Association, found antibiotics didn't ease patients' symptoms or get them back to work any sooner than an inactive placebo pill.

"There is not much to be gained from antibiotics," said Dr. Jane Garbutt of Washington University School of Medicine in St. Louis, who led the work.

"Rather than give everybody an antibiotic hoping to find the ones with bacteria, our findings would suggest refraining from antibiotics and doing what we call watchful waiting," she told Reuters Health.

That involves keeping an eye on patients to see if they get better, but not using other drugs than over-the-counter painkillers.

People with sinus infections, also called acute sinusitis, have lasting and severe cold-like symptoms such as runny nose and pain around the eyes, the nose or the forehead.

"It's the fifth most common reason antibiotics are prescribed for adults," said Garbutt. "It's hard for doctors not to give an antibiotic because patients are so miserable and we don't have anything else to give them."

But it hasn't been clear whether the drugs actually work, and even the studies that have found some benefit see the majority of placebo-treated patients get better by themselves.

Garbutt and her colleagues used official U.S. guidelines to identify patients with sinus infections. They randomly assigned 166 adults to either placebo pills or a 10-day treatment with the antibiotic amoxicillin.

Based on patient ratings on a symptom scale known as the modified Sinonasal Outcome Test-16, or SNOT-16, the researchers found little difference between the two patient groups.

Using the aptly named scale, where 0 equals "no problem" and 3, a "severe problem," the antibiotic group rated their symptoms at 1.12 after three days, while the placebo group averaged 1.14. After seven days, there were signs of benefit from the antibiotic, but the effect was small and had vanished another three days later.

Neither were there differences in how many work days patients missed, how satisfied they were with their treatment, how often they relapsed or how much additional medical care they got.

After 10 days, 78 percent of the people on antibiotics and 80 percent of the placebo-treated people said they felt a lot better or no longer had symptoms.

Dr. Anthony Chow, an expert in infectious diseases at the University of British Columbia in Vancouver, Canada, said less than two percent of sinus infections are bacterial.

"Most cases are viral, and the vast majority don't require antibiotics," he told Reuters Health. "Antibiotics have been abused, so there is a need to be more cautious in prescribing them and to hold back."

But Chow said antibiotics still have a place.

He recently chaired a committee at the Infectious Diseases Society of America, which has developed guidelines to help spot infections that are more likely to be bacterial.

Those guidelines, still in press, recommend treating only patients whose symptoms last for at least 10 days and keep worsening; who are severely sick with high fever and other symptoms; or who improve and then get worse again.

SOURCE: http://bit.ly/A4EKuo JAMA, February 14, 2012.


View the original article here

Thứ Tư, 15 tháng 2, 2012

WHO calls for stepped-up fight against leprosy

The World Health Organization called Monday for greater efforts to fight leprosy, warning the disfiguring disease was defying efforts to wipe it out across many countries in the Asia-Pacific region.

"We opened the champagne too early," said Shin Young-soo, chairman of the WHO's Western-Pacific region that covers 37 countries at the start of a three-day conference looking at how to combat leprosy and treat its victims.

There are 5,000 new cases being reported each year in the Western Pacific, according to Shin.

He said the problem was most severe in Micronesia, the Marshall Islands and Kiribati, which had failed to meet the WHO's technical definition of "elimination" of fewer than one case per 10,000 people.

Even in the Philippines, where the disease was officially "eliminated" in 1998, 2,000 new cases are still recorded every year, according to Shin.

Outside of the Western Pacific, the problem is worse.

India leads the world with more than 130,000 new leprosy cases every year since 2006, while Brazil is second with about 40,000 new cases annually, according to WHO documents.

Shin called for a renewed commitment to fight leprosy, stressing that it had to be long-term because the disease could incubate for as long as 20 years.

"We have the drugs, we have the knowledge. It does not take a lot of money. We must make a final push," he said.

Leprosy is an infectious bacterial disease that has been recorded for thousands of years. If left untreated it can damage the nerves, leading to paralysis in the extremities of the body and horrible disfigurements.

However it is curable with early detection and modern drugs.

The WHO has been providing free drug therapy to patients anywhere in the world since 1995.

Shin said that, with the medical hurdles overcome, the major challenge in countries with enduring leprosy was to ensure long-term commitment from governments.


View the original article here

Antibiotics no help against most sinus infections: study

(Reuters) - Antibiotics don't help fight most sinus infections, although doctors routinely prescribe them for that purpose, according to a U.S. study.

Researchers whose work was published in the Journal of the American Medical Association found that antibiotics didn't ease patients' symptoms or get them back to work any sooner than an inactive placebo pill.

Antibiotics are known to fuel the evolution of drug-resistant bacteria and experts have grown increasingly worried about overuse.

This is a particular concern with sinus infections, because doctors can't tell if the disease is caused by bacteria or by a virus, in which case antibiotics are useless.

"There is not much to be gained from antibiotics," said Jane Garbutt of Washington University School of Medicine in St. Louis, who led the study.

"Rather than give everybody an antibiotic hoping to find the (patients) with bacteria, our findings would suggest refraining from antibiotics and doing what we call watchful waiting," she told Reuters Health.

That involves keeping an eye on patients to see if they get better, but not using drugs other than over-the-counter painkillers.

People with sinus infections, also called acute sinusitis, have lasting and severe cold-like symptoms such as a runny nose and pain around the eyes, nose or forehead.

"It's the fifth most common reason antibiotics are prescribed for adults. It's hard for doctors not to give an antibiotic because patients are so miserable, and we don't have anything else to give them," said Garbutt.

Garbutt and her colleagues used official U.S. guidelines to identify patients with sinus infections. They randomly assigned 166 adults to either placebo pills or a 10-day treatment with the antibiotic amoxicillin.

Based on patient ratings on a symptom scale known as the modified Sinonasal Outcome Test-16, or SNOT-16, the researchers found little difference between the two patient groups.

Using the scale, where 0 equals "no problem" and 3 a "severe problem," the antibiotic group rated their symptoms at 1.12 after three days, while the placebo group averaged 1.14.

After seven days, there were signs of benefit from the antibiotic, but the effect was small and had vanished another three days later.

After 10 days, 78 percent of the people on antibiotics and 80 percent of the placebo-treated people said they felt a lot better or no longer had symptoms.

Fewer than two percent of sinus infections are bacterial, said Anthony Chow, an expert in infectious diseases at the University of British Columbia in Vancouver, Canada.

"Most cases are viral, and the vast majority don't require antibiotics," he said.

"Antibiotics have been abused, so there is a need to be more cautious in prescribing them and to hold back."

But he said that antibiotics still do have a place and recently chaired a committee at the Infectious Diseases Society, which has developed guidelines to help spot infections that are more likely to be bacterial.

Those guidelines, still in press, recommend treating only patients whose symptoms last for at least 10 days and keep worsening, who are severely sick with high fever and other symptoms, or who improve and then get worse again. SOURCE: http://bit.ly/A4EKuo

(Reporting from New York by Frederik Joelving at Reuters Health; editing by Elaine Lies and Bob Tourtellotte)


View the original article here

Thứ Tư, 8 tháng 2, 2012

FDA panel votes against wider use of Amgen drug

WASHINGTON (Reuters) - An advisory panel on Wednesday recommended that U.S. health regulators reject the use of Amgen Inc's drug Xgeva to delay the spread of prostate cancer to the bone, dimming the chance of a wider use for one of the company's key growth drivers.

The outside advisers to the Food and Drug Administration voted 12-to-1 that the benefits of the injectable drug, known chemically as denosumab, did not outweigh the risk of developing a jawbone-destroying condition.

Xgeva is already approved to prevent fractures and related problems in advanced prostate cancer that has spread to the bone, and the company is seeking additional approval for use of the drug to delay or prevent the spread.

The drug did delay the spread of cancer to the bone by a little longer than four months in a clinical trial of 1,432 men with prostate cancer who had stopped responding to hormone therapy.

But about one in 15 men who took the drug developed osteonecrosis of the jaw, a severe side effect in which jawbone tissue dies, exposing the bone. That rate is far higher than has been seen with widely used osteoporosis drugs.

"If you ask a patient, 'Do you want to delay your disease by five minutes, but get significant toxicities?' I think that would give them pause," said panel member Maha Hussain, a professor of medicine in the hematology and oncology division at the University of Michigan.

The FDA usually follows the recommendations of its expert panels and will make a final decision by April 26.

Most analysts had expected the unfavorable panel vote because the FDA had questioned whether delaying the spread of cancer to the bone was a meaningful benefit to patients given that the drug did not help men live longer or delay the growth of prostate cancer..

"We believe the panel recommendation reinforces the FDA's view, which has been consistently negative, and approval is unlikely," said Geoff Meacham, analyst at JP Morgan, in a research note.

However, he said the risk of a rejection of wider approval for Xgeva had only a modest risk to his long-term revenue estimates for Amgen, the world's largest biotechnology company.

BENEFIT TO PATIENTS?

Xgeva and a related osteoporosis drug Prolia are seen as among the most important growth drivers for Amgen and are expected to help offset declining sales of the anemia drugs that had been the company's backbone.

In the fourth quarter of 2011, sales of Xgeva rose to $134 million from $100 million in the prior quarter, and it is expected to eventually become a $1 billion-a-year drug.

The company said the new use for Xgeva would be targeted at about 50,000 men in the United States at that advanced stage of the disease.

Panel members questioned whether using the drug earlier actually benefited patients, as many did not have symptoms of the disease, but would suffer any drug-related side effects.

However, the patient representative on the panel voted in favor of approval.

"There isn't a treatment that a man with prostate cancer gets that doesn't have devastating effects on his masculinity and his quality of life," said James Kiefert, of Olympia, Washington. "In my opinion, the men who would be candidates for this treatment would be standing up and cheering another option for them."

His views echoed the favorable comments of several urologists, who testified in favor of the drug during the public hearing.

Amgen said Xgeva provided a meaningful benefit to prostate cancer patients by preventing the spread of their disease to the bones, which is not uncommon.

"We look forward to further discussions with the FDA as they continue to review our application," the company said in a statement after the vote.

If Xgeva gains wider approval, it would be the first drug to delay the spread of prostate cancer to the bone, Amgen said.

Amgen said it was also testing Xgeva in other cancers, including breast and lung cancer and the blood cancer multiple myeloma.


View the original article here